{"id":"W3099980423","doi":"10.1182/blood-2020-143816","title":"Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Bosutinib; Medicine; Open label; Myeloid leukemia; Internal medicine; Phases of clinical research; Oncology; Adverse effect; Clinical trial; Imatinib; Nilotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00269104,0.001558632,0.00182096,0.0004280978,0.00058903,0.001104125,0.0008295316,0.001586246,0.00501301],"category_scores_gemma":[0.001842748,0.0006381274,0.001928772,0.0004688167,0.001053966,0.001389422,0.0004205953,0.00392838,0.001021508],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001120842,"about_ca_system_score_gemma":0.001381231,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006266064,"about_ca_topic_score_gemma":0.001502387,"domain_scores_codex":[0.9992042,0.0004063262,0.00005324618,0.0001392262,0.00007540776,0.0001216152],"domain_scores_gemma":[0.9981133,0.0003947576,0.0004877098,0.0001115027,0.0001282407,0.0007644414],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9101372,0.03061896,0.0046917,0.0004789862,0.0008520841,0.0001104124,0.0001481306,0.001210208,0.01272636,0.0001394829,0.002694423,0.03619202],"study_design_scores_gemma":[0.5565884,0.4224455,0.01549709,0.00004672171,0.000701592,0.0002073403,0.00004449365,0.0008580843,0.001822151,0.0001956444,0.001562335,0.0000308262],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906099,0.002833866,0.0003914841,0.0004823836,0.0001095695,0.001552961,0.002353937,0.00006663559,0.001599195],"genre_scores_gemma":[0.9914023,0.001229794,0.0007732355,0.0007578655,0.0002249042,0.001373482,0.003067304,0.00002122071,0.001149957],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00501301,"threshold_uncertainty_score":0.01677024,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02238647833757712,"score_gpt":0.2837266180933452,"score_spread":0.261340139755768,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}